Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Active Ankylosing Spondylitis
NCT02008916Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2014
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of secukinumab in ankylosing spondylitis (AS), sponsored by Novartis. Started Jan 2014; status: completed.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT02008916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02008916.